BERKELEY, Calif., April 11, 2019-- Today, Fauna Bio, a biotechnology company leveraging the science of hibernation to improve healthcare for humans, announced that it has raised a total of $4.1 million in seed funding led by True Ventures with strong participation by Longevity Fund and Pacific 8 Ventures, in addition to Boom Capital and Beagle Ventures. The company will use the new funds to expand its discovery platform to help find new therapeutic targets for human diseases. The first version of Fauna Bio's drug-discovery platform focuses on hibernating mammals, a particularly attractive opportunity for adaptation-inspired therapeutics.